Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Vistagen Therapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of VTGN: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders1162112−2
Shares135.4M43.4K138.8M+3.45M (+2.5%)
Value$167.8M$54.0K$122.1M−$45.7M (−27.2%)

2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (20)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to VTGN in Q2 2022
InstitutionSharesValue% of portfolio
MAI Capital Management2,661,398$2.34M0.05%
Soleus Capital Management, L.P.825,000$726.0K0.12%
UBS Oconnor LLC381,500$336.0K0.00%
Assenagon Asset Management S.A.360,475$317.0K0.00%
Caption Management, LLC337,500$297.0K0.03%
HAP Trading, LLC331,587$292.0K0.04%
Group One Trading, L.P.135,844$120.0K0.00%
Belvedere Trading LLC138,385$112.0K0.12%
Simplex Trading, LLC48,514$42.0K0.00%
United Bank37,940$33.0K0.00%
Ergoteles LLC29,500$26.0K0.00%
Pinz Capital Management, LP19,000$17.0K0.01%
Xponance, Inc.10,552$9.00K0.00%
GPS Wealth Strategies Group, LLC7,143$6.00K0.00%
Selective Wealth Management, Inc.3,500$3.00K0.00%
Moneta Group Investment Advisors LLC2,273$2.00K0.00%
High Net Worth Advisory Group LLC1,950$2.00K0.00%
Curi Capital1,238$1.00K0.00%
Credit Suisse AG98$00.00%
FNY Investment Advisers, LLC1,000$00.00%

Sold out (22)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Not filed for Q2 2022 yet (2)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VTGN in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Amalgamated Financial Corp.30,350$38.0K
Parametric Portfolio Associates LLC13,029$16.0K